Boston Scientific Builds Neurovascular Scale With US$14.5b Penumbra Deal

Simply Wall St.01-27

Boston Scientific (NYSE:BSX) announced an agreement to acquire Penumbra in a deal valued at about US$14.5b. The transaction expands Boston Scientific's reach into the neurovascular market, adding to ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2606780655?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/company-cover/317627-main-header/1756255518234","is_english":true,"pubTime":"2026-01-27 19:30","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2606780655","market":"us","top_or_hot":-1,"title":"Boston Scientific Builds Neurovascular Scale With US$14.5b Penumbra Deal","media":"Simply Wall St.","content":"<div>\n<p>Boston Scientific (NYSE:BSX) announced an agreement to acquire Penumbra in a deal valued at about US$14.5b. The transaction expands Boston Scientific's reach into the neurovascular market, adding to ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/healthcare/nyse-bsx/boston-scientific/news/boston-scientific-builds-neurovascular-scale-with-us145b-pen\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Boston Scientific Builds Neurovascular Scale With US$14.5b Penumbra Deal</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBoston Scientific Builds Neurovascular Scale With US$14.5b Penumbra Deal\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-01-27 19:30 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/healthcare/nyse-bsx/boston-scientific/news/boston-scientific-builds-neurovascular-scale-with-us145b-pen><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Boston Scientific (NYSE:BSX) announced an agreement to acquire Penumbra in a deal valued at about US$14.5b. The transaction expands Boston Scientific's reach into the neurovascular market, adding to ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/healthcare/nyse-bsx/boston-scientific/news/boston-scientific-builds-neurovascular-scale-with-us145b-pen\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4581","symbol_name":"高盛持仓","start_time":0,"source_url":"https://simplywall.st/stocks/us/healthcare/nyse-bsx/boston-scientific/news/boston-scientific-builds-neurovascular-scale-with-us145b-pen","article_id":"2606780655","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/company-cover/317627-main-header/1756255518234"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/healthcare/nyse-bsx/boston-scientific/news/boston-scientific-builds-neurovascular-scale-with-us145b-pen","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2606780655","pubTimestamp":1769513442,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Boston Scientific (NYSE:BSX) announced an agreement to acquire Penumbra in a deal valued at about US$14.5b.\nThe transaction expands Boston Scientific's reach into the neurovascular market, adding to its cardiovascular-focused portfolio.\nThe company has highlighted the acquisition as a major step in its long term growth and diversification plans.\n\nFor you as an investor, this move puts a spotlight on how Boston Scientific is positioning itself across both cardiovascular and neurovascular...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4581":"高盛持仓","LU1791710582.SGD":"Fidelity Global Demographics A-ACC-SGD (SGD/USD hedged)","LU1548497426.USD":"安联环球人工智能AT Acc","LU2491050154.USD":"WELLINGTON SUSTAINABLE OUTCOMES \"A\" (USD) ACC","LU1366192091.USD":"ALLIANZ US EQUITY PLUS \"AM\" (USD) INC","LU0823417653.USD":"BNP PARIBAS SUSTAINABLE GLOBAL LOW VOL EQUITY \"C\" (USD) ACC","LU1718418525.SGD":"JPMorgan Investment Funds - Global Select Equity A (acc) SGD","SG9999013999.USD":"UOB UNITED GLOBAL HEALTHCARE FUND (USDHDG) INC","LU2265009873.SGD":"Eastspring Investments - Global Growth Equity AS SGD-H","LU2242649171.HKD":"FIDELITY FUNDS GLOBAL THEMATIC OPPORTUNITIES \"A\" (HKD) ACC","LU1791710400.SGD":"Fidelity Global Demographics A-ACC-SGD","LU2112291526.USD":"BGF WORLD HEALTHSCIENCE \"A4\" (USD) INC","LU0011850046.USD":"贝莱德全球长线股票 A2 USD","LU1061106388.HKD":"BGF WORLD HEALTHSCIENCE \"A2\" (HKDHDG) ACC","LU1023059063.AUD":"BGF WORLD HEALTHSCIENCE \"A2\" (AUDHDG) ACC","LU1804176565.USD":"EASTSPRING INV GLOBAL GROWTH EQUITY \"A\" (USD) ACC","BK4585":"ETF&股票定投概念","LU0048584097.USD":"FIDELITY FUNDS  GLOBAL THEMATIC OPPORTUNITIES \"A\" (USD) INC","IE00BFTCPJ56.SGD":"Janus Henderson Global Life Sciences A Acc SGD","LU1291159041.SGD":"CPR Invest - Global Silver Age A2 Acc SGD-H","IE00B4R5TH58.HKD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (HKD) ACC","LU0353189680.USD":"富国美国全盘成长基金Cl A Acc","LU0345769128.USD":"NINETY ONE GSF GLOBAL EQUITY \"A\" (USD) ACC","LU0882574055.USD":"富达全球健康医疗A ACC","LU0267386448.USD":"FIDELITY FIRST ALL COUNTRY WORLD \"A\" (USD) INC","LU0225283273.USD":"SCHRODER ISF GLOBAL EQUITY ALPHA \"A\" (USD) ACC","LU0823416689.USD":"BNP PARIBAS HEALTH CARE INNOVATORS \"C\" (USD) ACC","BSX":"波士顿科学","LU0122379950.USD":"贝莱德世界健康科学A2","LU1983299246.USD":"SCHRODER ISF HEALTHCARE INNOVATION \"A\" (USD) ACC","IE0002141913.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (USD) ACC","LU0251132253.USD":"FIDELITY FUNDS  GLOBAL THEMATIC OPPORTUNITIES \"A\" (USD) ACC","BK4504":"桥水持仓","LU1720051017.SGD":"Allianz Global Artificial Intelligence AT Acc H2-SGD","LU0432979614.USD":"JPM GLOBAL HEALTHCARE \"A\" ACC","LU2324357040.USD":"HSBC GIF GLOBAL EQUITY SUSTAINABLE HEALTHCARE \"AC\" (USD) ACC","IE00BJJMRZ35.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (SGDHDG) ACC","LU0823417737.USD":"BNP PARIBAS SUSTAINABLE GLOBAL LOW VOL EQUITY \"C\" (USD) INC","LU0077335932.USD":"FIDELITY AMERICAN GROWTH \"A\" INC","LU0266013472.USD":"AXA WF - Framlington Longevity Economy A Cap USD","BK4548":"巴美列捷福持仓","LU1153585028.USD":"BGF GLOBAL LONG-HORIZON EQUITY  \"A4\" (USD) INC","LU0950375773.USD":"BNP PARIBAS SUSTAINABLE GLOBAL LOW VOL EQUITY \"C\" (USD) INC A","LU0353189763.USD":"ALLSPRING  US ALL CAP GROWTH FUND \"I\" (USD) ACC","IE0009355771.USD":"骏利亨德森环球生命科技A Acc","SG9999001176.SGD":"UOB UNITED GLOBAL HEALTHCARE \"SGD\" (ACC)","PEN":"Penumbra Inc","LU2362540622.SGD":"WELLINGTON NEXT GENERATION GLOBAL EQUITY \"A\" (SGDHDG) ACC","LU2491050071.SGD":"WELLINGTON SUSTAINABLE OUTCOMES \"A\" (SGDHDG) ACC","IE00B2B36J28.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I1\" (USD) INC"},"translate_title":"Boston Scientific通过14.5 B美元的Penumbra交易打造神经血管规模","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PEN":1.5,"BSX":1.5},"content_text":"Boston Scientific (NYSE:BSX) announced an agreement to acquire Penumbra in a deal valued at about US$14.5b. The transaction expands Boston Scientific's reach into the neurovascular market, adding to its cardiovascular-focused portfolio. The company has highlighted the acquisition as a major step in its long term growth and diversification plans.  For you as an investor, this move puts a spotlight on how Boston Scientific is positioning itself across both cardiovascular and neurovascular care. The company already operates in a wide range of medical device categories, and Penumbra brings products focused on conditions such as stroke and other neurovascular disorders. This combination ties into a broader industry focus on treating complex, high acuity conditions with device based therapies. Management has acknowledged that the acquisition could be dilutive to earnings in the short term, with expectations that it could become accretive over time. As the deal progresses, you may want to watch how Boston Scientific integrates Penumbra's product lines and how the company communicates its plans for margins, capital allocation, and balance sheet flexibility. Stay updated on the most important news stories for Boston Scientific by adding it to your watchlist or portfolio. Alternatively, explore our Community to discover new perspectives on Boston Scientific. NYSE:BSX 1-Year Stock Price Chart Why Boston Scientific could be great value Boston Scientific's agreement to acquire Penumbra for an enterprise value of about US$14.5b extends its recent push into neurology related devices, building on earlier deals for Nalu Medical and Valencia Technologies and its existing spinal cord stimulation franchise. For you, this clusters more of the company’s growth efforts around high acuity conditions in both the brain and chronic pain. That, in turn, could make Boston Scientific more exposed to procedure trends in these therapy areas and to competitive responses from peers such as Medtronic in adjacent cardiac segments. AdvertisementBoston Scientific narrative, sharpened by a bigger neurovascular push Even without a formal narrative attached here, this deal fits the story many investors already watch for Boston Scientific, a company leaning into device based treatments for complex cardiovascular and neurological conditions. The Penumbra acquisition may reinforce views that management is willing to deploy sizable capital into higher growth niches. At the same time, the size of the transaction could also prompt some investors to reassess how much of the recent earnings and revenue momentum they attribute to organic performance versus deal activity. Risks and rewards investors are weighing  🎁 The acquisition increases Boston Scientific's exposure to neurovascular and neuromodulation markets, which some investors see as attractive therapy areas. 🎁 Recent earnings and revenue trends, as well as prior analyst enthusiasm, suggest investors have already been rewarding the company for portfolio expansion in higher complexity care. ⚠️ The US$14.5b price tag has already led at least one analyst to lower a price target, highlighting concern that the financial optics of the deal may be demanding. ⚠️ Management has signaled that the deal may be dilutive to earnings in the near term, which can increase sensitivity to how quickly integration benefits show up in margins.  What to watch from here From here, it is worth tracking how Boston Scientific outlines integration milestones for Penumbra, including any updates on expected earnings impact, margin trends, and capital allocation priorities as the deal closes. You can also keep an eye on how broader investor conversations evolve by following the latest community views and narrative threads in one place through this dedicated hub.  This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.Valuation is complex, but we're here to simplify it.Discover if Boston Scientific might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2606780655","isCrawlerRequest":true}